Compare Abeona Therapeutics Inc (ABEO) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Ross Stores, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Ross Stores, Inc. trades at $216.37 (market cap $68.86B). The key difference: Ross Stores, Inc. is far larger — about 184.5× Abeona Therapeutics Inc's market cap, and Ross Stores, Inc. pays a 0.83% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ROST | |
|---|---|---|
Market Cap | $373.32M | $68.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $240.13 |
52-Week Low | $4.17 | $127.59 |
Enterprise Value | $228.22M | $69.45B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Ross Stores (ROST) trades at $214.67, up 0.58% today, with strong fundamentals including 9.74% net income margin and 38.98% ROE. Recent earnings beats and a consensus price target of $259.00 suggest upside potential. Technicals are bearish near-term, but positive news highlights robust sales growth and expansion. Cash flow trends show volatility, with 2025 net cash flow negative but projected to rebound in 2026.
Outlook is positive driven by earnings momentum and store expansion, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is bullish with 64% buy ratings, supporting a growth-oriented view for investors seeking retail exposure with solid profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
